CLS-AX (axitinib injectable suspension)

About clearside-biomedical

Clearside Biomedical is revolutionizing ocular therapeutics through its proprietary suprachoroidal space (SCS) delivery platform. The company's mission is to preserve and improve vision by enabling targeted, in-office administration of therapies directly to the choroid, retina, and macula. Its strategy is validated by the commercial approval of XIPERE® and is centered on advancing its lead internal asset, CLS-AX for wet AMD, into Phase 3, while leveraging its platform through strategic collaborations with other biopharma companies to expand the pipeline across multiple retinal indications.

Therapeutic Areas